Scarica l'app Stockscreener
39.96
2.94%
-1.21
Precedente Chiudi:
$41.17
Aprire:
$41.76
Volume 24 ore:
1.45M
Relative Volume:
1.21
Capitalizzazione di mercato:
$2.85B
Reddito:
-
Utile/perdita netta:
$-299.62M
Rapporto P/E:
-8.5679
EPS:
-4.6639
Flusso di cassa netto:
$-241.73M
1 W Prestazione:
+2.28%
1M Prestazione:
-5.35%
6M Prestazione:
+68.11%
1 anno Prestazione:
+44.47%
Intervallo 1D:
$38.89
$42.73
Intervallo di 1 settimana:
$38.00
$45.38
Portata 52W:
$18.53
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Nome
Vera Therapeutics Inc
Settore
Industria
Telefono
650-770-0077
Indirizzo
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
39.96 | 2.85B | 0 | -299.62M | -241.73M | -4.6639 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-16 | Iniziato | BofA Securities | Buy |
| 2025-08-04 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2025-01-28 | Iniziato | Goldman | Buy |
| 2024-11-21 | Iniziato | Wells Fargo | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-25 | Iniziato | Oppenheimer | Outperform |
| 2024-01-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Iniziato | Raymond James | Outperform |
| 2023-11-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-16 | Iniziato | Guggenheim | Buy |
| 2023-01-04 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-04 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-12 | Iniziato | JP Morgan | Overweight |
| 2022-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-19 | Iniziato | Wedbush | Outperform |
Mostra tutto
Vera Therapeutics Inc Borsa (VERA) Ultime notizie
Wall Street analysts see a 53.05% upside in Vera Therapeutics (VERA): Can the stock really move this high? - MSN
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision - The Motley Fool
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision - The Motley Fool
Published on: 2026-03-13 13:04:33 - baoquankhu1.vn
Aug Big Picture: What is the cash position of Vera Therapeutics Inc2026 Price Action Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Vera Therapeutics urges expanded innovation in global kidney health on World Kidney Day - Traders Union
Wolfe Research upgrades Vera Therapeutics (VERA) - MSN
Quarterly Trades: Can Vera Therapeutics Inc deliver consistent EPS growth2026 Investor Takeaways & Community Shared Stock Ideas - baoquankhu1.vn
Vera Therapeutics (NASDAQ:VERA) Upgraded to Outperform at Wolfe Research - MarketBeat
How (VERA) Movements Inform Risk Allocation Models - Stock Traders Daily
Wolfe Research upgrades Vera Therapeutics stock rating on valuation By Investing.com - Investing.com Canada
Vera Therapeutics (NASDAQ:VERA) Trading Up 10.2%What's Next? - MarketBeat
Vera Therapeutics’ Atacicept Gains FDA Priority, Stock Soars - StocksToTrade
Vera Therapeutics stock rating reaffirmed at Buy by BofA Securities - Investing.com Canada
Vera Therapeutics Adds Christopher Hite to Board - TipRanks
Director at Vera Therapeutics (VERA) receives grant of 24,937 stock options - Stock Titan
Director Christopher Hite files initial Form 3 at Vera Therapeutics (VERA) - Stock Titan
Vera Therapeutics Appoints New Board Member - Intellectia AI
Can Vera Therapeutics Inc. stock deliver surprise earnings beat2026 EndofYear Setup & Weekly Return Optimization Plans - Naître et grandir
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Six new Vera Therapeutics hires receive 4-year stock awards - Stock Titan
Vanguard Group Inc. Has $92.72 Million Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics Appoints Christopher Hite to Board of Directors - Sahm
Vera Therapeutics adds Christopher Hite to board of directors By Investing.com - Investing.com Canada
Vera Therapeutics adds Christopher Hite to board of directors - Investing.com
Vera Therapeutics appoints Christopher Hite to board of directors - marketscreener.com
Vera Therapeutics Appoints Christopher Hite To Board Of Directors - TradingView
Royalty Pharma vice chair joins Vera board before potential IgA drug launch - Stock Titan
Q1 EPS Estimates for Vera Therapeutics Cut by HC Wainwright - MarketBeat
Vera Therapeutics Files BLA for Atacicept in IgAN, Target Action Date July 7, 2026 - Intellectia AI
Vera Therapeutics, Inc. (VERA) Stock Analysis: 94.88% Potential Upside Signals Compelling Opportunity - DirectorsTalk Interviews
Insider Sells $90,298 in Vera Therapeutics Stock - National Today
HC Wainwright Issues Positive Forecast for Vera Therapeutics (NASDAQ:VERA) Stock Price - MarketBeat
VERA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HC Wainwright & Co. Raises Price Target on Vera Therapeutics (VE - GuruFocus
Positive Phase 3 IgA Data and FDA Priority Review Could Be A Game Changer For Vera Therapeutics (VERA) - simplywall.st
Trading Systems Reacting to (VERA) Volatility - Stock Traders Daily
Key facts: Vera Therapeutics submits atacicept BLA; posts $299.6M loss - TradingView
Wedbush Raises Price Target on Vera Therapeutics to $35 From $33, Keeps Neutral Rating - marketscreener.com
Does FDA Priority Review And Phase 3 Win For Atacicept Redefine The Bull Case For Vera (VERA)? - Yahoo Finance
Vera Therapeutics, Inc. SEC 10-K Report - TradingView
VERA: Net loss widened to $299.6M as R&D and G&A spending surged ahead of potential atacicept approval - TradingView
Atacicept progress puts Vera Therapeutics (NASDAQ: VERA) at key FDA milestone - Stock Titan
Vera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Vera Therapeutics Raises $261M in Public Offering at $42.50 per Share - Intellectia AI
VERA: FDA priority review and strong cash reserves set the stage for atacicept's 2026 launch - TradingView
BRIEF-Vera Therapeutics FY EPS USD -4.66 Vs. IBES Estimate USD -4.55 - TradingView
Vera Therapeutics (VERA) widens 2025 loss as atacicept wins FDA priority review - Stock Titan
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results - GlobeNewswire
Vera Therapeutics (NASDAQ:VERA) SVP Sells $130,851.66 in Stock - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Insider Laurence Matthew Skelton Sells 1,582 Shares - MarketBeat
Vera Therapeutics Inc Azioni (VERA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):